70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here <<

David Mott Biography and Net Worth

Director of Novavax

Mr. Mott is currently a private investor through Mott Family Capital. He serves as chairman of the board for Adaptimmune, Ardelyx, Epizyme, Imara, and Mersana. From 2008 to 2020, Mr. Mott was general partner at NEA, one of the world’s largest venture capital firms, which invests in companies across all stages in healthcare and technology. Mr. Mott served as president and chief executive officer, vice chairman of MedImmune from 2000 through 2008, during which he led the sale of the company to AstraZeneca in June 2007 for $15.6 billion. He joined MedImmune in 1992 and served in various senior roles during his tenure, including chief operating officer and chief financial officer. During the course of his career, Mr. Mott has been involved in more than $40 billion in corporate acquisitions, fundraising, partnerships, and other capital formation. He has supported more than 35 initial public offerings or corporate acquisitions, brought in more than a dozen new drugs through development to commercialization, and served on 25 corporate boards. Mr. Mott holds a bachelor of arts degree from Dartmouth College.

What is David M. Mott's net worth?: The estimated net worth of David M. Mott is at least $1.01 million as of March 25th, 2021. Mr. Mott owns 116,414 shares of Novavax stock worth more than $1,012,802 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Mott may own. Learn More about David M. Mott's net worth.
How do I contact David M. Mott?: The corporate mailing address for Mr. Mott and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]. Learn More on David M. Mott's contact information.
Has David M. Mott been buying or selling shares of Novavax?: David M. Mott has not been actively trading shares of Novavax over the course of the past ninety days. Most recently, David M. Mott sold 24,961 shares of the business's stock in a transaction on Thursday, September 23rd. The shares were sold at an average price of $252.90, for a transaction totalling $6,312,636.90. Learn More on David M. Mott's trading history.
Who are Novavax's active insiders?: Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (President, CEO & Director), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.
Are insiders buying or selling shares of Novavax?: During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 62,312 shares worth more than $866,211.80. The most recent insider tranaction occured on June, 21st when Director James F Young sold 7,500 shares worth more than $105,675.00. Insiders at Novavax own 1.0% of the company. Learn More about insider trades at Novavax.
Information on this page was last updated on 6/21/2024.

David M. Mott Insider Trading History at Novavax

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/23/2021	Sell	24,961	$252.90	$6,312,636.90

David M. Mott Buying and Selling Activity at Novavax

Novavax Company Overview

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $8.70

$8.37

$8.89

50 Day Range

MA: $9.13

$7.22

$12.62

2 Week Range

Now: $8.70

$3.53

$23.86

Volume

6,086,848 shs

Average Volume

9,218,745 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02